The revenue cliff and EPS miss confirm Bolt is a pre-revenue clinical-stage biotech burning cash with no near-term catalyst until Q3 2026 data. The $23.9M cash runway into 2027 provides some buffer but offers no fundamental improvement. Traders should watch for potential dilutive financing given the $9M market cap and ongoing burn.
Price Chart
Executive Summary
Bolt Biotherapeutics reported Q1 2026 EPS of -$4.31, missing consensus of -$3.60 by 19.7%, and collaboration revenue collapsed 98% YoY to $26K. Cash burn narrowed to $8M in operating cash flow, leaving $23.9M in cash expected to fund operations into 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$4.31 vs consensus -$3.60 (19.7% miss)
- Collaboration revenue $26K vs $1.2M YoY (97.9% decline)
- Net loss -$7.2M improved from -$11.0M YoY on cost cuts
- Cash $23.9M expected to fund operations into 2027
- Operating cash burn -$8.0M vs -$13.4M YoY
- BDC-4182 Phase 1/2 initial data expected Q3 2026
- All pipeline programs except BDC-4182 on hold
Financial Impact
EPS miss of $0.71 (19.7%) on consensus -$3.60; revenue collapse of $1.2M (97.9%) YoY
Risk Factors
- Cash runway limited to ~3 quarters at current burn rate
- BDC-4182 clinical data delay or negative readout could impair stock
- Potential dilutive equity offering given $9M market cap
- All pipeline programs on hold, single-asset risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293366 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 3 | $6.58 | awaiting T+5 | — | $6.37 (−3.19%) |
Oct 23, 2026 4d ago | 8-K | $6.27 | awaiting T+5 | — | $6.37 (+1.59%) |
Oct 6, 2026 21d ago | 8-K | $3.60 $3.98 | ▼ −10.56% | ▼ −11.54% | $6.37 (−76.94%) |
May 12, 2026 24w ago | 8-K | $4.83 $4.72 | ▼ −2.28% | ▼ −1.12% | $6.37 (+31.88%) |
May 12, 2026 24w ago | Press Release | $4.83 $4.72 | ▲ +2.28% | ▲ +1.12% | $6.37 (−31.88%) |
Mar 12, 2026 32w ago | Press Release | $3.91 $4.76 | ▲ +21.74% | ▲ +23.86% | $6.37 (+62.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers